Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
4 results loaded, newest first. End of these results.
Ultragenyx Pharmaceutical entered a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher for $210 million, subject to customary closing conditions including expiration of the HSR waiting period.
Ultragenyx said it has entered a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher for $210 million. Closing is subject to customary conditions, including the Hart-Scott-Rodino waiting period.
Ultragenyx Pharmaceutical entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher for $210 million.
Ultragenyx entered into an agreement to sell a Rare Pediatric Disease Priority Review Voucher for $210 million.